Gsk (GSK) Invested Capital (2009 - 2026)

Gsk (GSK) has 18 years of Invested Capital data on file, last reported at -$8.7 billion in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital rose 22.97% year-over-year to -$8.7 billion; the trailing twelve-month figure through Jun 2026 stood at -$8.7 billion (up 22.97% YoY), and the FY2025 full-year result was -$9.5 billion, up 25.67% from the prior year.
• Invested Capital was -$8.7 billion for Q2 2026 at Gsk, up from -$9.3 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $16.2 billion in Q1 2022 to a low of -$23.3 billion in Q3 2022.
• A 5-year average of -$11.8 billion and a median of -$12.2 billion in 2024 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital surged 214.37% in 2022 and sank 214.17% in 2023, its largest moves.
• Gsk's Invested Capital stood at -$19.6 billion in 2022, then soared by 31.24% to -$13.4 billion in 2023, then gained by 4.45% to -$12.8 billion in 2024, then advanced by 25.97% to -$9.5 billion in 2025, then increased by 8.77% to -$8.7 billion in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were -$8.7 billion in Q2 2026, -$9.3 billion in Q1 2026, and -$9.5 billion in Q4 2025.